Janux Therapeutics, Inc.

JANX

Explore Our Financial Data > Companies > Janux Therapeutics, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
JANX
CIK0001817713
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
Website januxrx.com
Phone(858) 751-4493
CEODavid Campbell
Employees30

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$9.34 million
Pre-Tax Income$-77.74 million
Net Income$-77.74 million
Net Income to Common$-77.74 million
EPS$-1.36
View All
Balance Sheet
Cash$73.74 million
Assets$1.05 billion
Liabilities$38.30 million
Common Equity$1.01 billion
Liabilities & Equity$1.05 billion
View All
Cash Flow Statement
Net Income$-77.74 million
Cash From Operating Activities$-46.00 million
Cash From Investing Activities$-484.68 million
Cash From Financing Activities$391.62 million
Change in Cash$-139.06 million
View All
Calculations
NOPAT$-79.51 million
EBITDA$-124.56 million
Price to EarningsN/A
Price to Book$1.38
ROE-9.32%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

SAN DIEGO, July 24, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company’s continued momentum in advancing its novel immunother

Article Link

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

SAN DIEGO, July 17, 2025--Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Article Link

CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: TD Cowen upgraded Texas Instruments (TXN) to Buy from Hold with a price target of $245, up from $200. Texas Instruments is positioned to outperform in either a sharp or gradual recovery, the firm tells investors in a research note. Scotiabank upgraded Thermo Fisher (TMO) to Outperform from Sector Perfo

Article Link

CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls

CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls

Article Link

JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating with a $90 price target. The analyst based the rating on the company’s promising developments and future potential. […]

Article Link